Study wrapper · #957

Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients.

Seidl-Philipp M, Schratter H, Auer J, et al. Journal der Deutschen Dermatologischen Gesellschaft. 2026.

Editor's note

This real-world cohort of 20 patients reports large improvements in quality of life and pain-free light tolerance with afamelanotide, alongside reductions in phototoxic reactions and only mild transient side effects. As an uncontrolled observational study it supports rather than proves benefit, but it aligns with prior clinical-trial findings for this approved orphan indication. Note this is the regulated pharmaceutical form of melanotan-1, distinct from unregulated tanning use.

Plain-language abstract

A real-world study of 20 Austrian patients found that afamelanotide (melanotan-1) was associated with markedly longer pain-free sun exposure, better quality of life, and fewer phototoxic reactions in erythropoietic protoporphyria.

Weak / none